· We are pleased to note the high level activity of Yuanjia Bio to start building awareness of  VagiVital® in preparation of the full commercial launch, says Dr Johan Inborr, CEO of Peptonic Medical. The pre-launch promotion and sale of  VagiVital® is a smart way of introducing the Product in the market. Through its market research in China, Yuanjia Bio has identified four primary target patient groups for VagiVital®, including e.g. menopausal and post-partum (nursing) women, with a total number of approximately 415 million women. China’s so called ‘gyneacological inflammatory market’ was estimated to reach 26.9 billion yuan (approx. 3.5 billion Euro) in sales in 2018. Between 2013 and 2017, this market grew at a rate of 7.6 percent annually.